In the intent-to-treat population, the median progression-free survival (PFS) was 8.77 months with giredestrant plus Afinitor ...
Hosted on MSN
The DESTINY Trial: New Drug Combo Can Keep HER2-Positive Metastatic Breast Cancer Under Control For Longer
Data presented at 2025’s American Society of Clinical Oncology (ASCO) conference indicates that more people facing advanced breast cancer may be able to put off treatment with harsh chemotherapy in ...
Publication of positive data in a leading peer-reviewed journal enhances credibility and visibility for FemBloc, attracting interest from the medical community. The reported pregnancy rate of 0% among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback